Evolus, Inc. (EOLS): debt financing — Evolus refinances with $250M credit facility, cuts interest cost by 350 bps

Evolus, Inc.

New $250M senior secured term loan replaces existing $125M facility; $150M drawn at closing, $100M incremental capacity available in two $50M tranches through Dec 31, 2026.
Interest rate reduced by 350 bps to SOFR + 5.00% (floor 3.50%); quarterly interest payments, bullet maturity at 5 years.
Converted from amortizing to bullet maturity; significantly reduced prepayment fees; no additional performance conditions or financial covenants for incremental tranches.
Evolus no longer required to make principal payments in 2026; refinancing enhances cash generation and financial flexibility.
Funds managed by Pharmakon Advisors, LP; Leerink Partners served as exclusive financial advisor.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Evolus, Inc. incurred term loan of up to $250,000,000 with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP at 3-month Secured Overnight Financing Rate (“SOFR”) plus 5.0% per annum (subject t maturing 5th year anniversary of the Tranche A Closing Date.

Instrument: term loan
Principal: up to $250,000,000
Counterparty: BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP
Rate: 3-month Secured Overnight Financing Rate (“SOFR”) plus 5.0% per annum (subject t
Maturity: 5th year anniversary of the Tranche A Closing Date
Event: incurrence

Exact text from the filing

the Lenders agreed to make term loans to the Company in an aggregate principal amount of up to $250,000,000

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

Evolus, Inc. filing history →

Source: SEC EDGAR

accession 0001570562-25-000069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.